Go Pro
→ Your 401(k) May Not Be Ready for This (From Priority Gold) (Ad)tc pixel Free TRVI Stock Alerts

Trevi Therapeutics (TRVI) Short Interest Ratio & Short Volume

Trevi Therapeutics logo
$18.32 -0.19 (-1.02%)
As of 10:00 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Trevi Therapeutics Short Interest Overview

As of July 15, 2026, Trevi Therapeutics (TRVI) had a short interest of 12.65 million shares sold short, representing 10.53% of the public float. This marks a -8.77% decrease in short interest since the prior report. The short interest ratio (days to cover) is 4.8, meaning it would take 4.8 days of the average trading volume of 1.73 million shares to cover all short positions.

Current Short Interest
12,653,483 shares
Previous Short Interest
13,870,118 shares
Change Vs. Previous Month
-8.77%
Dollar Volume Sold Short
$229.66 million
Short Interest Ratio
4.8 Days to Cover
Last Record Date
July 15, 2026
Outstanding Shares
142,480,000 shares
Short Percent of Float
10.53%
Today's Trading Volume
36,464 shares
Average Trading Volume
1,733,312 shares
Today's Volume Vs. Average
2%
Short Selling Trevi Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Trevi Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

TRVI Short Interest Over Time

TRVI Days to Cover Over Time

TRVI Percentage of Float Shorted Over Time

Trevi Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/202612,653,483 shares $229.66 million -8.8%10.5%4.76 $18.15
6/30/202613,870,118 shares $258.68 million -3.4%12.0%4 $18.65
6/15/202614,351,654 shares $210.40 million +5.7%12.4%14.77 $14.66
5/29/202613,574,699 shares $191.95 million +2.2%11.7%12.4 $14.14
5/15/202613,289,352 shares $188.71 million -13.1%11.5%8.71 $14.20
4/30/202615,291,551 shares $210.41 million -5.3%13.2%6.72 $13.76
4/15/202616,139,168 shares $230.31 million +5.5%13.9%13.44 $14.27
3/31/202615,295,203 shares $182.70 million -7.0%12.7%11.25 $11.95
3/13/202616,442,993 shares $181.04 million -2.2%13.7%12.1 $11.01
2/27/202616,813,915 shares $200.42 million +5.0%14.0%15.09 $11.92
2/13/202616,010,995 shares $166.51 million +3.3%13.8%11.99 $10.40
1/30/202615,504,499 shares $162.33 million -0.3%12.9%9.79 $10.47
1/15/202615,556,094 shares $167.38 million +10.3%12.9%11.06 $10.76
12/31/202514,105,563 shares $176.60 million +3.3%11.7%9.56 $12.52
12/15/202513,651,656 shares $172.15 million +1.9%11.4%5.22 $12.61
11/28/202513,403,743 shares $176.33 million -9.3%11.2%6.24 $13.16
11/14/202514,784,433 shares $168.10 million -5.4%14.1%9.78 $11.37
10/31/202515,623,820 shares $182.17 million +7.1%15.7%10.69 $11.66
10/15/202514,590,000 shares $154.95 million -1.6%14.7%6.8 $10.62
9/30/202514,830,000 shares $135.69 million +22.7%N/A6.7 $9.15
9/15/202512,090,000 shares $97.45 million +3.5%N/A5.5 $8.06
8/31/202511,680,000 shares $84.80 million +15.5%11.7%5.8 $7.26
8/15/202510,110,000 shares $76.03 million -0.5%N/A5.3 $7.52
7/31/202510,160,000 shares $75.29 million +2.1%10.2%5.4 $7.41
7/15/20259,950,000 shares $68.26 million +6,352.7%N/A5.4 $6.86
6/30/2025154,200 shares $843.47 thousand -98.0%0.2%1.2 $5.47
6/15/20257,630,000 shares $46.47 million +8.7%8.0%4.4 $6.09
5/31/20257,020,000 shares $45.63 million +2.2%12.1%2.6 $6.50
5/15/20256,870,000 shares $42.53 million -1.2%11.8%3 $6.19
4/30/20256,950,000 shares $48.02 million +17.6%N/A3.1 $6.91
4/15/20255,910,000 shares $36.64 million +7.5%10.2%2.8 $6.20
3/31/20255,500,000 shares $34.60 million +17.5%9.5%2.8 $6.29
3/15/20254,680,000 shares $31.59 million +23.5%8.1%2.5 $6.75
2/28/20253,790,000 shares $17.13 million -12.5%6.5%1.4 $4.52
2/15/20254,330,000 shares $17.62 million -5.7%7.4%2.5 $4.07
1/31/20254,590,000 shares $18.08 million +11.1%N/A2.7 $3.94
1/15/20254,130,000 shares $15.78 million +6.7%N/A2.4 $3.82
12/31/20243,870,000 shares $15.94 million -17.0%N/A2.3 $4.12
12/15/20244,660,000 shares $19.43 million +230.5%N/A2.8 $4.17
11/30/20241,410,000 shares $4.06 million -19.4%N/A2.8 $2.88
This tiny piece of glass could be bigger than GPUs (Ad)

Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capital - the firm behind Anthropic and OpenAI - calls it a 'holy grail.' It's smaller than a fingertip and made of glass. Wall Street insider Jason Bodner - who called Nvidia at $4.50 - believes this 'light-speed' device could be bigger for AI than GPUs and is about to launch a new wave of winners. He's sharing his number one stock pick tied to it at no cost.tc pixel

Click here to get Jason Bodner's top pick for free
11/15/20241,750,000 shares $4.81 million +1.7%N/A3.7 $2.75
10/31/20241,720,000 shares $5.07 million +13.2%N/A4.4 $2.95
10/15/20241,520,000 shares $4.83 million +0.7%N/A4.6 $3.18
9/30/20241,510,000 shares $5.04 million +8.6%N/A5.7 $3.34
9/15/20241,390,000 shares $4.68 million -10.3%N/A5.4 $3.37
8/31/20241,550,000 shares $4.90 million +3.3%N/A6.8 $3.16
8/15/20241,500,000 shares $4.13 million +16.3%N/A6.6 $2.75
7/31/20241,290,000 shares $4.10 million +1.6%N/A5.6 $3.18
7/15/20241,270,000 shares $3.62 million +32.6%N/A5.6 $2.85
6/30/2024957,600 shares $2.85 million -0.4%N/A4.4 $2.98
6/15/2024961,000 shares $2.55 million +13.1%N/A4.8 $2.65
5/31/2024849,600 shares $2.18 million -13.9%N/A4 $2.57
5/15/2024986,400 shares $2.73 million -6.1%N/A4.2 $2.77
4/30/20241,050,000 shares $3.08 million +16.9%N/A3.6 $2.93
4/15/2024898,400 shares $2.52 million -13.6%N/A3 $2.81
3/31/20241,040,000 shares $3.59 million -2.8%N/A3.5 $3.45
3/15/20241,070,000 shares $3.58 million -13.7%N/A3.8 $3.35
2/29/20241,240,000 shares $3.62 million +4.2%N/A4.2 $2.92
2/15/20241,190,000 shares $2.83 million -13.8%N/A2.7 $2.38
1/31/20241,380,000 shares $1.96 million +11.3%N/A3.6 $1.42
1/15/20241,240,000 shares $1.76 million +6.0%N/A3.2 $1.42
12/31/20231,170,000 shares $1.57 million +15.8%N/A3.1 $1.34
12/15/20231,010,000 shares $1.29 million -7.3%N/A2.8 $1.28
11/30/20231,090,000 shares $1.23 million -4.4%N/A3.4 $1.13
11/15/20231,140,000 shares $1.57 million -1.7%N/A6.4 $1.38
10/31/20231,160,000 shares $2.06 million -4.9%N/A14 $1.78
10/15/20231,220,000 shares $2.48 million -3.2%N/A18.8 $2.03
9/30/20231,260,000 shares $2.75 million -4.6%N/A17.5 $2.18
9/15/20231,320,000 shares $3.10 million +0.8%N/A14.1 $2.35
8/31/20231,310,000 shares $2.90 million -3.7%N/A6.5 $2.21
8/15/20231,360,000 shares $3.29 million +3.0%N/A4.1 $2.42
7/31/20231,320,000 shares $3.14 million +1.5%N/A3.6 $2.38
7/15/20231,300,000 shares $2.81 million -2.3%N/A3.3 $2.16
6/30/20231,330,000 shares $3.18 million +482.8%N/A3.5 $2.39
6/15/2023228,200 shares $588.76 thousand -5.9%N/A0.6 $2.58
5/31/2023242,600 shares $524.02 thousand -2.1%N/A1 $2.16
5/15/2023247,900 shares $654.46 thousand -11.6%N/A1.5 $2.64
4/30/2023280,300 shares $964.23 thousand +39.2%N/A3.4 $3.44
4/15/2023201,300 shares $380.46 thousand +15.4%N/A3.2 $1.89
3/31/2023174,400 shares $322.64 thousand +51.9%N/A3.6 $1.85
3/15/2023114,800 shares $210.08 thousand +73.2%N/A1.1 $1.83
2/28/202366,300 shares $158.46 thousand -15.8%N/A0.6 $2.39
2/15/202378,700 shares $201.47 thousand -11.6%N/A0.7 $2.56
1/31/202389,000 shares $207.37 thousand -7.0%N/A0.8 $2.33
1/15/202395,700 shares $250.73 thousand +0.8%N/A0.8 $2.62
12/30/202294,900 shares $183.16 thousand -40.6%N/A0.7 $1.93
12/15/2022159,800 shares $356.35 thousand -34.2%N/A0.8 $2.23
11/30/2022242,800 shares $456.46 thousand -16.3%N/A1.2 $1.88
11/15/2022289,900 shares $637.78 thousand -1.9%N/A1.2 $2.20
10/31/2022295,600 shares $585.29 thousand -27.0%N/A1.1 $1.98
The ultimate IPO unicorn (Ad)

Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milestone. Its valuation exceeds every American airline combined and even tops the U.S. defense budget. The company's annualized revenue grew 80 times over in the first quarter alone. Anthropic has already filed IPO paperwork, with some estimates pointing to a public debut as early as October.tc pixel

Click here to learn how to access this pre-IPO opportunity
10/15/2022405,100 shares $725.13 thousand +264.0%N/A1.3 $1.79
9/30/2022111,300 shares $171.40 thousand +12.5%N/A0.3 $1.54
9/15/202298,900 shares $306.59 thousand -9.9%N/A0.1 $3.10
8/31/2022109,700 shares $348.85 thousand -2.3%0.6%0.1 $3.18
8/15/2022112,300 shares $424.49 thousand -19.1%0.6%0.1 $3.78
7/31/2022138,800 shares $424.73 thousand -29.9%1.1%0.1 $3.06
7/15/2022198,100 shares $691.37 thousand +99.3%1.5%0.1 $3.49
6/30/202299,400 shares $279.31 thousand +10.3%0.8%0.1 $2.81
6/15/202290,100 shares $199.12 thousand -29.7%0.8%0.1 $2.21
5/31/2022128,100 shares $310.00 thousand -48.5%1.1%0.2 $2.42
5/15/2022248,800 shares $549.85 thousand -37.4%2.2%0.2 $2.21
4/30/2022397,500 shares $1.07 million -27.6%11.7%0.3 $2.70
4/15/2022548,900 shares $1.80 million +66.6%3.9%0.5 $3.28
3/31/2022329,400 shares $724.68 thousand -60.4%2.3%0.3 $2.20
3/15/2022832,300 shares $1.22 million +40.9%N/A1.3 $1.46
2/28/2022590,800 shares $378.11 thousand +286.9%4.5%1 $0.64
2/15/2022152,700 shares $79.25 thousand +95.5%1.2%0.6 $0.52
1/31/202278,100 shares $49.80 thousand +4.3%0.8%0.3 $0.64
1/15/202274,900 shares $53.83 thousand -34.9%0.8%0.3 $0.72
12/31/2021115,100 shares $90.03 thousand +16.6%1.2%0.2 $0.78
12/15/202198,700 shares $70.77 thousand +16.7%1.0%0.2 $0.72
11/30/202184,600 shares $84.14 thousand -42.2%1.2%0.2 $0.99
11/15/2021146,400 shares $161.04 thousand -8.3%2.1%0.3 $1.10
10/29/2021159,700 shares $187.65 thousand +14.3%2.8%0.4 $1.18
10/15/2021139,700 shares $180.21 thousand +25.9%2.4%0.4 $1.29
9/30/2021111,000 shares $155.40 thousand +26.1%1.5%0.4 $1.40
9/15/202188,000 shares $123.20 thousand +43.1%1.2%1.5 $1.40
8/31/202161,500 shares $102.09 thousand -23.8%0.8%0.8 $1.66
8/13/202180,700 shares $162.61 thousand +11.3%1.1%1.2 $2.02

TRVI Short Interest - Frequently Asked Questions

Short interest is the volume of Trevi Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 15th, traders have sold 12,653,483 shares of TRVI short. 10.53% of Trevi Therapeutics' shares are currently sold short. Learn More on Trevi Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TRVI shares currently have a short interest ratio of 4.8. Learn More on Trevi Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.53% of Trevi Therapeutics' floating shares are currently sold short.

Trevi Therapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 12,653,483 shares, a decline of 8.8% from the previous total of 13,870,118 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

10.53% of Trevi Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceuticals" compare to Trevi Therapeutics: Dr. Reddy's Laboratories Ltd (2.56%), Crinetics Pharmaceuticals, Inc. (6.12%), Alkermes plc (9.44%), Liquidia Corporation (18.64%), Lantheus Holdings, Inc. (10.00%), Belite Bio, Inc. Sponsored ADR (3.78%), Amneal Pharmaceuticals, Inc. (3.08%), Edgewise Therapeutics, Inc. (11.90%), Indivior PLC (9.32%), Veradermics, Incorporated (9.42%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($73.09 billion), Invesco QQQ ($48.11 billion), iShares Russell 2000 ETF ($23.61 billion), Sandisk Corporation ($12.69 billion), Nebius Group N.V. ($12.18 billion), Western Digital Corporation ($11.95 billion), SPDR S&P Biotech ETF ($11.73 billion), Quhuo Limited Sponsored ADR ($9.74 billion), VanEck Semiconductor ETF ($9.57 billion), and Financial Select Sector SPDR Fund ($8.43 billion). View all of the most shorted stocks.

Short selling TRVI is an investing strategy that aims to generate trading profit from Trevi Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Trevi Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TRVI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TRVI, twice per month. The most recent reporting period available is July, 15 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like TRVI:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:TRVI) was last updated on 7/24/2026 by MarketBeat.com Staff.
From Our Partners
The ultimate IPO unicorn
Anthropic is now worth more than a trillion dollars, making it the first private company to reach that milesto...
Weiss Ratings | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Barricks gold output fell from 2 million ounces to 719000
Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...
Golden Portfolio | Sponsoredtc pixel
China is not hedging. It's escaping.
China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...
Behind the Markets | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Beginner’s Guide to Gold
The Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...
Goldco Direct, LLC | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel